Cover Image
市場調查報告書

全球微泡沫/超音波顯影劑市場:機會分析與產業預測

Microbubbles / Ultrasound Contrast Agents Market - Global Opportunity Analysis And Industry Forecast (2018-2024)

出版商 Meticulous Market Research Pvt. Ltd. 商品編碼 607593
出版日期 內容資訊 英文 105 Pages
訂單完成後即時交付
價格
Back to Top
全球微泡沫/超音波顯影劑市場:機會分析與產業預測 Microbubbles / Ultrasound Contrast Agents Market - Global Opportunity Analysis And Industry Forecast (2018-2024)
出版日期: 2018年02月26日 內容資訊: 英文 105 Pages
簡介

本報告提供全球微泡沫/超音波顯影劑的市場調查分析,市場概要,各市場區隔的市場分析,各地區分析,競爭情形,企業簡介等系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場考察

  • 簡介
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
    • 趨勢

第5章 微泡沫/超音波顯影劑市場:各治療領域

  • 簡介
  • 心血管疾病
  • 腎臟病、相關疾病
  • 其他的疾病

第6章 微泡沫/超音波顯影劑市場:各用途

  • 簡介
  • 分子影像
  • 基因治療
  • 藥物輸送
  • 幹細胞輸送

第7章 微泡沫/超音波顯影劑市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第8章 競爭情形

  • 簡介
  • 核准
  • 夥伴關係,契約,聯盟
  • 事業擴大,其他

第9章 企業簡介

  • Lantheus Holdings, Inc.
  • Bracco
  • GE Healthcare
  • 第一三共
  • nanoPET Pharma GmbH

第10章 附錄

目錄
Product Code: MRPH-10409

Title:
Microbubbles/Ultrasound Contrast Agents Market
by Therapeutic Area (Cardiovascular Diseases, Renal and Associated Diseases, and others), by Application (Molecular Imaging, Gene Therapy, Drug Delivery, and Stem Cells Delivery) - Global Opportunity Analysis and Industry Forecasts To 2024.

Microbubbles/ultrasound contrast agents are small spherical bubbles comprised of three phases, namely innermost gas phase, shell material enclosing the gas phase, and outermost gas or liquid phase. These microbubbles have unique ability to respond to ultrasound; thereby used for ultrasound imaging and research. Global microbubbles/ultrasound contrast agents market is expected to reach USD 1,584.5 million by 2024, at a CAGR of 25.2% during the forecast period of 2018 to 2024.

Succeeding an extensive secondary and primary research on microbubbles/ultrasound contrast agents and in-depth analysis of the market scenario, the report carries out an impact analysis of the key industry drivers, restraints, opportunities, and trends in this market. The various factors such as technological advancements, benefits of ultrasound over alternative technologies, favorable reimbursement policies for contrast enhanced procedures in the U.S., increase in demand for diagnostics & image guided procedures, and growing aging population and subsequent rise in the prevalence of chronic diseases are majorly driving the growth of microbubbles/ultrasound contrast agents market. However, factors such as complexity involved in conducting contrast-enhanced ultrasound (CEUS) procedures hinder the growth of this market to some extent.

In addition, the report further gives an extensive outlook on ultrasound contrast agents market with respect to various therapeutic areas and applications. An in-depth analysis of the geographic scenario of the industry provides detailed qualitative and quantitative insights for the major geographies (North America, Europe, Asia-Pacific, and rest of the World). The geographic analysis provides detailed insights on the key trends of the industry in the listed regions, identifying the demographic & economic impact, and government & private investments. The report identifies North America to be the largest market followed by Europe, Asia Pacific, and Rest of World. The geographic analysis section also comments on the key market players shaping the growth of the industry in the respective regions.

The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2014-2017).

The key players in the global microbubbles/ultrasound contrast agents market are Lantheus Holdings, Inc., Bracco, GE Healthcare, Daiichi Sankyo Company, Limited, and nanoPET Pharma GmbH.

Scope of the report

Market by Therapeutic Area:

  • Cardiovascular diseases
  • Renal and associated diseases
  • Others

Market by Application:

  • Molecular imaging
  • Gene therapy
  • Drug delivery
  • Stem cells delivery

Market by Geography:

  • North America
  • Europe
  • Asia-Pacific (APAC)
  • Rest of the World

Table of Contents

1. Introduction

  • 1.1. Market Ecosystem
  • 1.2. Currency and Limitations
    • 1.2.1. Currency
    • 1.2.2. Limitations
  • 1.3. Key Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Secondary Research
    • 2.1.2. Primary Research
    • 2.1.3. Market Size Estimation

3. Executive Summary

4. Market Insights

  • 4.1. Introduction
  • 4.2. Market Dynamics
    • 4.2.1. Drivers
      • 4.2.1.1. Advancement in Ultrasound Technologies
        • 4.2.1.1.1. Evolution of Microbubbles
        • 4.2.1.1.2. Miniaturization of Ultrasound Devices
          • 4.2.1.1.2.1. Wearable Ultrasound Pain therapy Device
          • 4.2.1.1.2.2. Flow Focusing Microfluidic Devices (FFMDs)
          • 4.2.1.1.2.3. Handheld Ultrasound Scanners
          • 4.2.1.1.2.4. Phone-Based Ultrasound Systems
      • 4.2.1.2. Benefits over Alternative Technologies
      • 4.2.1.3. Favorable Reimbursement Policies for Ultrasound Contrast Enhanced Procedures in the U.S.
      • 4.2.1.4. Increase in Demand for Diagnostics & Image Guided Procedures influencing the Sales of Microbubbles
      • 4.2.1.5. Growing Aging Population and Subsequent Rise in the Prevalence of Chronic Diseases
    • 4.2.2. Restraints
      • 4.2.2.1. Complexity involved in Conducting Contrast Enhanced Ultrasound (CEUS) Procedures
    • 4.2.3. Opportunities
      • 4.2.3.1. Rising Microbubbles/ Ultrasound Contrast Agents Related Research
    • 4.2.4. Trends
      • 4.2.4.1. Expansion- A Key Growth Strategy Adopted by Market Players

5. Microbubbles/Ultrasound Contrast Agents Market, by Therapeutic Area

  • 5.1. Introduction
  • 5.2. Cardiovascular Diseases
    • 5.2.1. Drivers
      • 5.2.1.1. High incidence of Stroke Worldwide
      • 5.2.1.2. Improvisation in therapies to Boost the Application in Sonothrombolysis
    • 5.2.2. Sonothrombolysis: Future Potential
      • 5.2.2.1. Prospects: Targeted Microbubbles
      • 5.2.2.2. Prospects: Gene Delivery
  • 5.3. Renal and Associated Diseases
    • 5.3.1. Ultrasound Applications in Kidney
      • 5.3.1.1. Diagnosis between Solid Renal Masses and Pseudo-Tumors
      • 5.3.1.2. Differentiation between Cystic and Solid Lesions of the Kidneys
      • 5.3.1.3. Characterization of Complex Cystic Renal Masses
      • 5.3.1.4. Renal infections
      • 5.3.1.5. Renal Trauma
      • 5.3.1.6. Renal Artery Stenosis
      • 5.3.1.7. Assessment of Percutaneous Ablation therapy
      • 5.3.1.8. Kidney Transplantation
      • 5.3.1.9. Kidney Fibrosis
    • 5.3.2. Drivers
      • 5.3.2.1. Regulatory Changes and Government Support to Boost Clinical Research Related to Kidney
    • 5.3.3. Restraints
      • 5.3.3.1. Retention of Microbubbles
  • 5.4. Other Diseases

6. Microbubbles/Ultrasound Contrast Agents Market, by Application

  • 6.1. Introduction
  • 6.2. Molecular Imaging
    • 6.2.1. Applications
    • 6.2.2. Trends
      • 6.2.2.1. Development of Novel Microbubbles to Improve Target Binding
      • 6.2.2.2. Development of Novel Microbubbles to Suit the Modalities Used in Imaging
    • 6.2.3. Challenges
      • 6.2.3.1. Currently Ultrasound Molecular Imaging Is Still in Its infancy and Some Challenges Exist
  • 6.3. Gene therapy
    • 6.3.1. Drivers
    • 6.3.2. Methods of Gene therapy
  • 6.4. Drug Delivery
    • 6.4.1. Drivers
      • 6.4.1.1. Growing Number of Researchers in the Field of Drug Delivery Using Microbubbles
      • 6.4.1.2. Rising incidence & Mortality of Cancer & Cardiac Disease to Create Need for Better Drug therapies
      • 6.4.1.3. Growing Researches involving Targeted Drug Delivery Using Microbubbles
  • 6.5. Stem Cell Delivery
    • 6.5.1. Growing Researches

7. Microbubbles/Ultrasound Contrast Agents Market, by Geography

  • 7.1. Introduction
  • 7.2. North America
  • 7.3. Europe
  • 7.4. Asia-Pacific
  • 7.5. Rest of the World

8. Competitive Landscape

  • 8.1. Introduction
  • 8.2. Approvals
  • 8.3. Partnerships, Agreements, and Collaborations
  • 8.4. Expansions & Others

9. Company Profiles

  • 9.1. Lantheus Holdings, Inc.
    • 9.1.1. Business overview
    • 9.1.2. Financial overview
    • 9.1.3. Product Portfolio
    • 9.1.4. Strategic Developments
  • 9.2. Bracco
    • 9.2.1. Business overview
    • 9.2.2. Financial overview
    • 9.2.3. Product Portfolio
    • 9.2.4. Strategic Developments
  • 9.3. GE Healthcare
    • 9.3.1. Business overview
    • 9.3.2. Financial overview
    • 9.3.3. Product Portfolio
    • 9.3.4. Strategic Developments
  • 9.4. Daiichi Sankyo Company, Limited
    • 9.4.1. Business overview
    • 9.4.2. Financial overview
    • 9.4.3. Products Portfolio
    • 9.4.4. Strategic Developments
  • 9.5. nanoPET Pharma GmbH
    • 9.5.1. Business overview
    • 9.5.2. Financial overview
    • 9.5.3. Product Portfolio
    • 9.5.4. Strategic Developments

10. Appendix

10.1. Questionnaire 10.2. Available Customization

List of Tables

  • Table 1: Global Microbubbles/Ultrasound Contrast Agents Market Drivers: Impact Analysis (2018-2024)
  • Table 2: Publications Related to Custom Microbubbles
  • Table 3: Comparison of Ultrasound Technologies over Other Technologies
  • Table 4: Medicare Payment for Contrast Enhanced Procedures (2016-2017)
  • Table 5: Global Microbubbles/Ultrasound Contrast Agents Market Restraints: Impact Analysis (2018-2024)
  • Table 6: List of Approved Microbubbles/Ultrasound Contrast Agents
  • Table 7: Global Microbubbles/Ultrasound Contrast Agents Market Size, by therapeutic Area, 2016-2024 (USD Million)
  • Table 8: Potentially Accessible Targets for Molecular Imaging with Ultrasound
  • Table 9: Global Microbubbles/Ultrasound Contrast Agents Market Size for Cardiovascular Diseases, by Region, 2016-2024 (USD Million)
  • Table 10: Behavior of Microbubbles in Kidney
  • Table 11: Comparison of the Pathological Entities on Baseline Ultrasound and CEUS
  • Table 12: Researches Related to Microbubbles Mediated Renal therapies
  • Table 13: Global Microbubbles/Ultrasound Contrast Agents Market Size for Renal & Associated Diseases, by Region, 2016-2024 (USD Million)
  • Table 14: Global Microbubbles/Ultrasound Contrast Agents Market Size for Other therapeutic Areas, by Region, 2016-2024 (USD Million)
  • Table 15: Global Microbubbles/Ultrasound Contrast Agents Market Size, by Application, 2016-2024 (USD Million)
  • Table 16: Production of Microbubbles for Molecular Imaging
  • Table 17: Global Microbubbles/Ultrasound Contrast Agents Market Size for Molecular Imaging, by Region, 2016-2024 (USD Million)
  • Table 18: Global Microbubbles/Ultrasound Contrast Agents Market Size for Gene therapy, by Region, 2016-2024 (USD Million)
  • Table 19: Global Microbubbles/Ultrasound Contrast Agents Market Size for Drug Delivery, by Region, 2016-2024 (USD Million)
  • Table 20: Global Microbubbles/Ultrasound Contrast Agents Market Size for Stem Cell Delivery, by Region, 2016-2024 (USD Million)
  • Table 21: Global Microbubbles/Ultrasound Contrast Agents Market Size, by Region, 2018-2024 (USD Million)
  • Table 22: North America: Microbubbles/Ultrasound Contrast Agents Market Size, by Application, 2016-2024 (USD Million)
  • Table 23: North America: Microbubbles/Ultrasound Contrast Agents Market Size, by therapeutic Area, 2016-2024 (USD Million)
  • Table 24: Europe: Microbubbles/Ultrasound Contrast Agents Market Size, by Application, 2016-2024 (USD Million)
  • Table 25: Europe: Microbubbles/Ultrasound Contrast Agents Market Size, by therapeutic Area, 2016-2024 (USD Million)
  • Table 26: Asia-Pacific: Microbubbles/Ultrasound Contrast Agents Market Size, by Application, 2016-2024 (USD Million)
  • Table 27: Asia-Pacific: Microbubbles/Ultrasound Contrast Agents Market Size, by therapeutic Area, 2016-2024 (USD Million)
  • Table 28: RoW: Microbubbles/Ultrasound Contrast Agents Market Size, by Application, 2016-2024 (USD Million)
  • Table 29: RoW: Microbubbles/Ultrasound Contrast Agents Market Size, by therapeutic Area, 2016-2024 (USD Million)

List of Figures

  • Figure 1: Market Ecosystem
  • Figure 2: Key Stakeholders
  • Figure 3: Research Process
  • Figure 4: Key Executives interviewed
  • Figure 5: Primary Research Techniques
  • Figure 6: Key Opportunity
  • Figure 7: Molecular Imaging Dominates the Global Microbubbles/Ultrasound Contrast Agents Market
  • Figure 8: Microbubbles/Ultrasound Contrast Agents Market overview: 2018-2024
  • Figure 9: Global Microbubbles/Ultrasound Contrast Agents Market by Geography, 2017
  • Figure 10: Worldwide Cost of Operations in 2013 (In Euro)
  • Figure 11: Proportion of Aged Population in the World, 2010-2016 (% of total Population)
  • Figure 12: Older Population Aged 60 Years or over in the World (In Million), 1950-2050
  • Figure 13: Top Countries Facing Greatest Skills Shortage in 2014 (In %)
  • Figure 14: Global Microbubbles/Ultrasound Contrast Agents Market Size, by therapeutic Area, 2018-2024 (USD Million)
  • Figure 15: Global Microbubbles/Ultrasound Contrast Agents Market Size, by Application, 2018-2024 (USD Million)
  • Figure 16: Global Microbubbles/Ultrasound Contrast Agents Market Size, by Geography, 2018-2024 (USD Million)
  • Figure 17: Number of Aged Population (Over 65) in U.S., 2000-2050 (In Million)
  • Figure 18: Share of total Alzheimer's Dementia Cases in U.S., by Age Group, 2017
  • Figure 19: Proportion of Canadians Aged 65 and Older with Major Chronic Diseases, 2014
  • Figure 20: Proportion of Aged Population (65 and over) in EU Countries, 2010-2016 (% of total Population)
  • Figure 21: Population Aged 65 and over by Region, 2015-2050
  • Figure 22: New Cases of Cardiovascular Diseases, 1990-2015 (In Million)
  • Figure 23: Proportion of Population Aged 65 and over in Asia-Pacific Countries, 2010-2016 (% of total Population)
  • Figure 24: Proportional Mortality in China by therapeutic Area, 2011
  • Figure 25: Proportion of Population Aged 65 and over in Latin American Countries, 2010-2016 (% of total Population)
  • Figure 26: Proportion of Population Aged 65 and over in Middle East and African Countries, 2010-2016 (% of total Population)
  • Figure 27: Reported Mortality by Non-Communicable Diseases in Africa, 2013 (In %)
  • Figure 28: GRoWth Strategies Adopted by the Key Players
  • Figure 29: Lantheus Holdings, Inc.: Financial overview (2014-2016)
  • Figure 30: Bracco: Financial overview (2016)
  • Figure 31: GE Healthcare: Financial overview (2014-2016)
  • Figure 32: Daiichi Sankyo Company, Limited: Financial overview (2014-2016)
Back to Top